Fermented Dairy Product and Bifidobacterium Diversity (ThreeBees)

Inclusion Criteria:

1. Male and female subjects aged between 45 and 60 years old.

2. BMI between 18.5 kg/m2 and 30 kg/m2.

3. Subjects who are overtly healthy as determined by the investigator.

4. Willing and/or able to:

• Speak and read in French,

• Collect, store and transport their faecal samples themselves,

• Consume the study products twice per day for 28 consecutive days and not toconsume any fermented dairy products during the entire study (other than thestudy products) as well as any probiotic, prebiotic or synbiotic supplementsduring the entire study.

• Complete the electronic Patient Reported Outcomes (ePRO) using their owndigital device having access to internet.

5. Willing to limit alcohol consumption and not to smoke or consume any soft or harddrug during the study.

6. Having access to adequate space to store the investigational products in their ownfridge at home.

7. Having regular bowel movements.

8. Signed written informed consent by the participant.

9. Female subjects must either be postmenopausal for at least 12 months or haveundergone specific surgical procedures resulting in sterility or they are using oneof the medically approved contraceptive methods.

10. Subject is covered by French health insurance.

11. Subject agrees to be registered in the national database of subjects participatingin clinical research.

Exclusion Criteria:

1. Any ongoing metabolic disease, hypertension, inflammatory disease, allergicconditions requiring chronic systemic medication, psychiatric disorder,gastrointestinal disorder, chronic pain, or neurological disorder diagnosed by aphysician.

2. Known allergy or intolerance to any ingredients or potential allergens.

3. Pregnancy or breast-feeding at the screening visit or plan for pregnancy during thestudy.

4. Any antecedents or plan for digestive or dental surgery, general anaesthesia or anyparticipation in another study with investigational or marketed products potentiallyaffecting the gut microbiota.

5. Unable (or unwilling) to adhere to protocol requirements (based on investigator'sjudgement).

6. Subject with a special diet at the screening visit, or plan for such diet during thestudy.

7. Major changes in subject's dietary habits ≤ 4 weeks before the screening visit orplan for such major changes during the study including change in vitamin or mineralsupplements use, but except for dietary restrictions related to the study.

8. Enhanced diet together with intense physical activity ≤ 4 weeks before the screeningvisit, plan for such a diet and training during the study, or plan for major changesin physical activity during the study.

9. Use ≤ 8 weeks before the screening visit or plan of use during the study of systemicmedication that can affect the gastrointestinal function or plan of use during thestudy (if needed, incidental use of ≤ 4 tablets of paracetamol, non-steroidalanti-inflammatory drugs (NSAIDs) or aspirin per 2-week period is allowed).

10. Subject with excessive alcohol consumption, active smoker or quit active smokingless than 5 years ago before the screening visit. Not regularly smoking is allowed.

11. Drug abuse based on investigator's judgement.

12. Living in the same home as others already participating in the study and toconcomitantly receive some study products.

13. Subject under guardianship, curatorship, person under judicial protection, familyempowerment or future protection mandate.

14. Employees, family members or other relatives of employees of the participatingcentre or of Danone Global Research & Innovation Center.